Medical Weight Management with GLP-1

Doctor-supervised GLP-1 weight loss programme combining semaglutide or liraglutide injection therapy with personalised nutrition guidance, exercise support, and regular medical monitoring for safe, sustained weight reduction.

Parkway Shenton's Medical Weight Management Programme is a clinically supervised, outcome-driven approach to obesity and overweight that addresses the biological drivers of weight gain — not just lifestyle. Priced from SGD 380 per month, the programme is available at selected Parkway Shenton clinics across Singapore and begins with a comprehensive medical assessment before any treatment is prescribed. The centrepiece of the programme for eligible patients is GLP-1 receptor agonist therapy. GLP-1 medications (such as semaglutide, marketed as Ozempic or Wegovy, or liraglutide as Saxenda) work by mimicking the natural glucagon-like peptide-1 hormone, which regulates blood sugar, slows gastric emptying, and significantly reduces appetite and food cravings. The medications are typically administered once weekly via subcutaneous self-injection, with dosage titrated gradually under medical supervision to optimise efficacy and minimise side effects. Beyond medication, the programme integrates personalised nutrition guidance from registered dietitians, an exercise prescription suited to the patient's current fitness level and health status, and regular progress reviews with the supervising doctor. The medical team monitors blood glucose, blood pressure, lipids, and kidney function throughout — essential for safe GLP-1 use in patients with metabolic comorbidities. Clinical evidence from large-scale trials (SUSTAIN, SCALE) shows that GLP-1 therapy combined with lifestyle intervention produces 10–15% weight loss over 12–18 months in most patients, with meaningful reductions in HbA1c, blood pressure, and cardiovascular risk. Parkway Shenton's programme follows this evidence base, setting realistic expectations while building the long-term habits needed to maintain results after medication tapering. The programme is suitable for adults with a BMI of 23 kg/m² or above (Asian threshold) or 27 kg/m² with weight-related comorbidities such as type 2 diabetes or hypertension. A WhatsApp enquiry line is available for initial questions.